CTLA4 and neoplasm: Approximately 10% of patients with advanced gastric cancer treated with anti-PD-1 antibodies experienced rapid disease progression, known as hyperprogressive disease (HPD), wherein PD-1-PD-L1 pathway blockade activated and expanded tumor-infiltrating PD-1+CTLA-4+ Tregs [145].